10-K Filing

TANKE BIOSCIENCES CORP CIK: 1452011 FY 2012

Filing Information

Form Type	10-K
Accession Number	`0001213900-13-001814`
Period End Date	20121231
Filing Date	20130415
Fiscal Year	2012
Fiscal Period	FY
XBRL Instance	tnbi-20121231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 86 Income Statement 44 Cash Flow Statement 77 Stockholders Equity 16

Balance Sheet 86 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.32M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.32M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.22M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$231.84K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.32M	shares	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$706.80K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.32M	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$1.92M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$1.99M	USD	Point-in-time
Inventories, net	`InventoryNet`	$1.41M	USD	Point-in-time
Inventories, net	`InventoryNet`	$1.19M	USD	Point-in-time
Note receivable-related parties	`DueFromRelatedPartiesCurrent`	-	USD	Point-in-time
Note receivable-related parties	`DueFromRelatedPartiesCurrent`	$239.48K	USD	Point-in-time
Loans to customer and supplier	`AccountsAndOtherReceivablesNetCurrent`	$2.51M	USD	Point-in-time
Loans to customer and supplier	`AccountsAndOtherReceivablesNetCurrent`	$2.89M	USD	Point-in-time
Other receivables	`OtherReceivables`	$483.88K	USD	Point-in-time
Other receivables	`OtherReceivables`	$53.94K	USD	Point-in-time
Prepayments	`AdvancesToSuppliers`	$3.63M	USD	Point-in-time
Prepayments	`AdvancesToSuppliers`	$9.03M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$132.75K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$914.59K	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsNetCurrent`	$46.04K	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsNetCurrent`	$27.04K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.91M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$22.37M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$4.77M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$4.81M	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$35.88K	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$295.25K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.24M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$838.09K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$134.74K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$328.01K	USD	Point-in-time
Total assets	`Assets`	$28.85M	USD	Point-in-time
Total assets	`Assets`	$24.89M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$784.78K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$646.65K	USD	Point-in-time
Advance from customers	`AdvancesFromCustomers`	$128.32K	USD	Point-in-time
Advance from customers	`AdvancesFromCustomers`	-	USD	Point-in-time
Other payables and accrued liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$942.79K	USD	Point-in-time
Other payables and accrued liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$758.91K	USD	Point-in-time
Income tax payable	`AccruedIncomeTaxesCurrent`	$1.22M	USD	Point-in-time
Income tax payable	`AccruedIncomeTaxesCurrent`	$1.84M	USD	Point-in-time
Convertible notes, net of discount	`ConvertibleDebtCurrent`	-	USD	Point-in-time
Convertible notes, net of discount	`ConvertibleDebtCurrent`	$7.27M	USD	Point-in-time
Current portion of long-term borrowing	`LongTermDebtCurrent`	$785.46K	USD	Point-in-time
Current portion of long-term borrowing	`LongTermDebtCurrent`	$1.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.55M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$12.10M	USD	Point-in-time
Convertible notes, net of discount	`ConvertibleDebtNoncurrent`	$4.49M	USD	Point-in-time
Convertible notes, net of discount	`ConvertibleDebtNoncurrent`	-	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$13.72K	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	-	USD	Point-in-time
Advance from government grant	`GovernmentGrantsForResearchAndDevelopmentProjectsOutstanding`	$37.95K	USD	Point-in-time
Advance from government grant	`GovernmentGrantsForResearchAndDevelopmentProjectsOutstanding`	$355.75K	USD	Point-in-time
Long-term borrowing, net of current portion	`LongTermDebtNoncurrent`	$792.57K	USD	Point-in-time
Long-term borrowing, net of current portion	`LongTermDebtNoncurrent`	$628.37K	USD	Point-in-time
Total liabilities	`Liabilities`	$12.93M	USD	Point-in-time
Total liabilities	`Liabilities`	$9.03M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of December 31, 2012 and December 31, 2011	`CommonStockValue`	$13.32K	USD	Point-in-time
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of December 31, 2012 and December 31, 2011	`CommonStockValue`	$13.32K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$12.22M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$12.22M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.70M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.49M	USD	Point-in-time
Statutory reserve	`StatutoryAccountingPracticesRetainedEarningsNotAvailableForDividends`	$373.41K	USD	Point-in-time
Statutory reserve	`StatutoryAccountingPracticesRetainedEarningsNotAvailableForDividends`	$373.41K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$658.87K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$551.41K	USD	Point-in-time
Total Tanke Biosciences Corporation stockholders' equity	`StockholdersEquity`	$15.85M	USD	Point-in-time
Total Tanke Biosciences Corporation stockholders' equity	`StockholdersEquity`	$15.75M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$171.44K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	-	USD	Point-in-time
Total Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.33M	USD	Point-in-time
Total Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.85M	USD	Point-in-time
Total Equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.92M	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$28.85M	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$24.89M	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net sales	`SalesRevenueNet`	$23.83M	USD	Annual
Net sales	`SalesRevenueNet`	$28.56M	USD	Annual
Costs of sales	`CostOfGoodsSold`	$18.62M	USD	Annual
Costs of sales	`CostOfGoodsSold`	$15.06M	USD	Annual
Gross profit	`GrossProfit`	$9.94M	USD	Annual
Gross profit	`GrossProfit`	$8.77M	USD	Annual
Selling expenses	`SellingExpense`	$2.46M	USD	Annual
Selling expenses	`SellingExpense`	$2.68M	USD	Annual
Administrative expenses	`GeneralAndAdministrativeExpense`	$2.57M	USD	Annual
Administrative expenses	`GeneralAndAdministrativeExpense`	$4.49M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$81.00K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$161.46K	USD	Annual
Income from operations	`OperatingIncomeLoss`	$4.53M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$1.74M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$95.83K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$295.56K	USD	Annual
Interest expense	`InterestExpense`	$1.36M	USD	Annual
Interest expense	`InterestExpense`	$1.45M	USD	Annual
Amortization of discount on notes	`AmortizationOfFinancingCosts`	$2.47M	USD	Annual
Amortization of discount on notes	`AmortizationOfFinancingCosts`	$2.78M	USD	Annual
Registration rights agreement expense	`RegistrationRightsAgreementExpense`	-	USD	Annual
Registration rights agreement expense	`RegistrationRightsAgreementExpense`	$-460.21K	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-2.45M	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$602.59K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$831.60K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$681.32K	USD	Annual
Net loss	`ProfitLoss`	$-229.01K	USD	Annual
Net loss	`ProfitLoss`	$-3.14M	USD	Annual
Non-controlling interest in loss of subsidiaries	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Non-controlling interest in loss of subsidiaries	`NetIncomeLossAttributableToNoncontrollingInterest`	$-18.76K	USD	Annual
Net loss attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$-210.25K	USD	Annual
Net loss attributable to Tanke Biosciences Corporation	`NetIncomeLoss`	$-3.14M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$107.59K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$56.63K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-121.42K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.08M	USD	Annual
Comprehensive loss attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-18.63K	USD	Annual
Comprehensive loss attributable to non-controlling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	-	USD	Annual
Comprehensive loss attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$-102.79K	USD	Annual
Comprehensive loss attributable to Tanke Biosciences Corporation	`ComprehensiveIncomeNetOfTax`	$-3.08M	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.24	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.08M	shares	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	13.32M	shares	Annual

Cash Flow Statement 77 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-229.01K	USD	Annual
Net loss	`ProfitLoss`	$-3.14M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$400.01K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$636.29K	USD	Annual
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$2.49M	USD	Annual
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	$2.47M	USD	Annual
Amortization of discount on convertible notes payable	`AmortizationOfFinancingCosts`	$2.78M	USD	Annual
Amortization of capitalized offering costs	`OtherAmortizationOfDeferredCharges`	$709.41K	USD	Annual
Amortization of capitalized offering costs	`OtherAmortizationOfDeferredCharges`	$798.91K	USD	Annual
Provision for bad debt	`ProvisionForDoubtfulAccounts`	$90.19K	USD	Annual
Provision for bad debt	`ProvisionForDoubtfulAccounts`	$103.42K	USD	Annual
Inventory provision	`InventoryWriteDown`	$377.00	USD	Annual
Inventory provision	`InventoryWriteDown`	$41.59K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$169.66K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$172.39K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-173.36K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$227.08K	USD	Annual
Note receivables and payables - related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-225.75K	USD	Annual
Note receivables and payables - related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-2.58M	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$426.46K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-108.86K	USD	Annual
Deferred tax asset	`IncreaseDecreaseInDeferredIncomeTaxes`	$26.95K	USD	Annual
Deferred tax asset	`IncreaseDecreaseInDeferredIncomeTaxes`	$-19.00K	USD	Annual
Prepayments	`IncreaseDecreaseInPrepaidExpense`	$5.35M	USD	Annual
Prepayments	`IncreaseDecreaseInPrepaidExpense`	$3.52M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-138.08K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$17.06K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-193.27K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$61.66K	USD	Annual
Advance from government grant	`IncreaseDecreaseInDeferredRevenue`	$-315.23K	USD	Annual
Advance from government grant	`IncreaseDecreaseInDeferredRevenue`	$274.17K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$153.42K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-138.13K	USD	Annual
Other payables and accrued liabilities	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$183.89K	USD	Annual
Other payables and accrued liabilities	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$457.11K	USD	Annual
Income tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$478.81K	USD	Annual
Income tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$625.30K	USD	Annual
Advance from customer	`IncreaseDecreaseInCustomerAdvances`	$-3.24K	USD	Annual
Advance from customer	`IncreaseDecreaseInCustomerAdvances`	$128.32K	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.18M	USD	Annual
Net cash (used in) provided by operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$3.65M	USD	Annual
Increase in loans to customer and supplier	`IncreaseDecreaseInAccountsAndOtherReceivables`	$379.41K	USD	Annual
Increase in loans to customer and supplier	`IncreaseDecreaseInAccountsAndOtherReceivables`	$2.51M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$856.36K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$701.02K	USD	Annual
Acquisition of new production technology	`PaymentsToAcquireIntangibleAssets`	$529.94K	USD	Annual
Acquisition of new production technology	`PaymentsToAcquireIntangibleAssets`	$481.17K	USD	Annual
60% investment in Qingyuan Tanke Bio-Technology	`ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries`	$190.07K	USD	Annual
60% investment in Qingyuan Tanke Bio-Technology	`ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries`	-	USD	Annual
Increase in cash due to acquisition of China Flying	`CashAcquiredFromAcquisition`	$76.08K	USD	Annual
Increase in cash due to acquisition of China Flying	`CashAcquiredFromAcquisition`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.67M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.53M	USD	Annual
Change in restricted cash	`IncreaseDecreaseInRestrictedCashAndInvestmentsForOperatingActivities`	$-474.96K	USD	Annual
Change in restricted cash	`IncreaseDecreaseInRestrictedCashAndInvestmentsForOperatingActivities`	$706.80K	USD	Annual
Net proceeds from issuance of convertible notes	`ProceedsFromConvertibleDebt`	$6.52M	USD	Point-in-time
Net proceeds from issuance of convertible notes	`ProceedsFromConvertibleDebt`	-	USD	Annual
Net proceeds from issuance of convertible notes	`ProceedsFromConvertibleDebt`	$6.52M	USD	Annual
Increase in bank borrowings	`ProceedsFromBankDebt`	$646.85K	USD	Annual
Increase in bank borrowings	`ProceedsFromBankDebt`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.82M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.12M	USD	Annual
Effect of exchange rate fluctuations on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-322.43K	USD	Annual
Effect of exchange rate fluctuations on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$57.74K	USD	Annual
Net increase (decrease) in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$5.48M	USD	Annual
Net increase (decrease) in cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.53M	USD	Annual
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.22M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$7.70M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.17M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.22M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$652.29K	USD	Annual
Cash paid for interest	`InterestPaid`	$634.46K	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$346.84K	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$249.92K	USD	Annual

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Percentage of investment on Qingyuan Tanke Bio-Technology	`MinorityInterestOwnershipPercentageByNoncontrollingOwners`	0.60	pure	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.33M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.85M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.92M	USD	Point-in-time
Effect of acquisition of China Flying	`EffectOfVieAgreementWithSubsidiary`	$-72.11K	USD	Annual
Effect of Share Exchange Agreement	`EffectOfShareExchangeAgreementAmount`	$54.60K	USD	Annual
Effect of Private Placement	`EffectOfPrivatePlacement`	$6.13M	USD	Annual
Shares issued for consulting services	`StockIssuedDuringPeriodValueIssuedForServices`	$2.49M	USD	Annual
Net loss	`ProfitLoss`	$-229.01K	USD	Annual
Net loss	`ProfitLoss`	$-3.14M	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$107.59K	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$56.63K	USD	Annual
60% investment on Qingyuan Tanke Bio-Technology	`NoncontrollingInterestIncreaseFromBusinessCombination`	$190.07K	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.33M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.85M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.92M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.